# A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT06313957** · PHASE1 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 42 (estimated)

## Conditions studied

- Relapsed B-cell Non-Hodgkin Lymphoma
- Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** LUCAR-20SP cells

## Key facts

- **NCT ID:** NCT06313957
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-14
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313957, "A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06313957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*